echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The New Coronary Inactivated Vaccine obtained positive medium-term safety data in Phase 3 clinical trials.

    The New Coronary Inactivated Vaccine obtained positive medium-term safety data in Phase 3 clinical trials.

    • Last Update: 2020-10-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Krlef is an inactivated new crown vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. in cooperation with a number of cooperative units.
    preclinical results of the vaccine have been published in the academic journal Science.
    april 16 this year, the vaccine entered phase 1/2 clinical studies and showed good safety.
    this year, Cochlear ZWEI and the Butantan Institute in Brazil reached a partnership to conduct a phase 3 clinical study in Kellefort, Brazil.
    , 9,000 volunteers aged 18-59 have been vaccinated in Brazil with two doses of Kellefort, according to a press release issued by the Butantan Institute in Brazil.
    35 percent of the volunteers showed mild adverse reactions after vaccination.
    the most common adverse reactions after the first vaccination were pain at the injection site (19%) and headache (15%).
    second vaccination, the most common adverse reactions were pain at the injection site (19%), headache (10%) and fatigue (4%).
    0.1% of the volunteers had low fever and no serious adverse reactions were reported.
    resources: s1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved October 20, 2020, from s Sinovac vaccine is safe, Brazil institute says. Retrieved October 20, 2020, from the Brazilian National Health Supervision Agency approved Beijing Kexing Zhongwei Biotechnology Co., Ltd. new crown inactivated vaccine Kelleford ™️ to carry out Phase III. Retrieved October 20, 2020, from.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.